Oragenics, Inc.
OGEN Healthcare Biotechnology
Oragenics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $37,700.00, down 71.3% from fiscal 2022. In the quarter to June 2026, EPS grew 81.6% and free cash flow fell 66.4%, each against the same quarter a year earlier.
Follow OGEN
Oragenics, Inc. (OGEN) P/E ratio
As of 16 October 2026, Oragenics, Inc. (OGEN) trades at a P/E ratio of 0.4×. Over the past ten years it has ranged from 0.0× (June 2026) to 0.5× (July 2026); the current reading is higher than 97% of that period. That is below the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2023 | 0.0× | — |
| Jun 2023 | 0.0× | — |
| Mar 2023 | 0.0× | — |
| Sep 2022 | 0.0× | — |
| 4 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BRTX Biorestorative Therapies, Inc. compare | n/m |
| SILO Silo Pharma, Inc. compare | n/m |
| PPBT Purple Biotech Ltd. Sponsored ADR compare | n/m |
| KAPA Kairos Pharma, Ltd. compare | n/m |
| VRAX Virax Biolabs Group Limited compare | n/m |
| CLSDQ Clearside Biomedical, Inc. compare | n/m |
| TRVN Trevena, Inc. compare | n/m |
| GNPX GENPREX compare | 0.0× |
| OGEN Oragenics, Inc. | 0.4× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)